The agreement to jointly identify and develop molecular glue degrader treatments for several therapeutic targets marks an evolution in the relationship between Proxygen and Merck.
Sangamo Therapeutics faces setbacks as Novartis and Biogen collaborations come to an end
Going forward, Sangamo said it will continue to investigate alternative options to advance these programs, including either internally or with another collaboration partner.
Eli Lilly strikes $630 million deal with Confo Therapeutics for non-opioid neuropathic pain drug